Cover Image
市場調查報告書

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6) :開發中產品分析

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 363572
出版日期 內容資訊 英文 112 Pages
訂單完成後即時交付
價格
Back to Top
組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6) :開發中產品分析 Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H2 2017
出版日期: 2017年09月30日 內容資訊: 英文 112 Pages
簡介

本報告提供組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6)的開發情形相關的資訊,各開發階段、藥物標的、作用機制、給藥途徑及各分子類型的分析,開發治療藥的企業概要,最新消息和新聞稿等資訊,為您概述為以下內容。

簡介

  • 調查範圍

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6)的概要

治療藥的開發

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):開發中的產品 - 各開發階段

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):開發中的產品 - 各治療範圍

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):開發中的產品 - 各適應症

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):企業開發中的產品

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):大學/機關開發中的產品

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):治療藥的評估

  • 各單劑療法/聯合治療產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6)的治療藥的開發企業

  • Acetylon Pharmaceuticals, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • HitGen LTD
  • Kancera AB
  • Karus Therapeutics Limited
  • Lycera Corp.
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • OncoHoldings, Inc.
  • Quimatryx, S.L.
  • Sigma-Tau S.p.A.
  • SK Biopharmaceuticals Co., Ltd.
  • 武田藥品工業
  • TetraLogic Pharmaceuticals

藥物簡介

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):暫停中的計劃

組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6):主要消息與新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1028TDB

Summary

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) pipeline Target constitutes close to 37 molecules. Out of which approximately 29 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase 6 - Pipeline Review, H2 2017, outlays comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Histone deacetylase 6 is an enzyme encoded by the HDAC6 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. It is involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. It plays a key role in the degradation of misfolded proteins. It acts as an adapter that recognizes polyubiquitinated misfolded proteins and target them to the aggresome, facilitating their clearance by autophagy. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 3, 14 and 8 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Immunology, Genetic Disorders, Toxicology, Dermatology and Infectious Disease which include indications Multiple Myeloma (Kahler Disease), Breast Cancer, Melanoma, Mantle Cell Lymphoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Solid Tumor, Alzheimer's Disease, Autoimmune Disorders, Charcot-Marie-Tooth Disease, Chemotherapy Induced Peripheral Neuropathy, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Depression, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lung Cancer, Lymphoma, Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alopecia, Anaplastic Thyroid Cancer, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Burkitt Lymphoma, CNS Lymphoma, Colon Cancer, Colon Tumor, Cutaneous T-Cell Lymphoma, Diabetic Neuropathic Pain, Endometrial Cancer, Fallopian Tube Cancer, Glioma, Human Papillomavirus (HPV) Associated Cancer, Huntington Disease, Inflammation, Liver Cancer, Lung Adenocarcinoma, Lupus Nephritis, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma, Multiple Sclerosis, Myelodysplastic Syndrome, Neuroblastoma, Neurodegenerative Diseases, Neurology, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Papillary Thyroid Cancer, Parkinson's Disease, Peritoneal Cancer, Polycystic Kidney Disease, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sepsis, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Systemic Lupus Erythematosus and Thyroid Cancer.

Furthermore, this report also reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
  • The report reviews Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Overview
    • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
    • Celgene Corp
    • Chong Kun Dang Pharmaceutical Corp
    • Curis Inc
    • HitGen LTD
    • Kancera AB
    • Karus Therapeutics Ltd
    • Medivir AB
    • Merck & Co Inc
    • Millennium Pharmaceuticals Inc
    • OnKure Inc
    • Quimatryx SL
    • Shuttle Pharmaceuticals LLC
    • Sigma-Tau SpA
    • SK Biopharmaceuticals Co Ltd
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Drug Profiles
    • ACY-1083 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACY-738 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACY-775 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C-1A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • citarinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-504 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-506 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-509 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CKD-L - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CUDC-907 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HG-3001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IKH-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KA-2507 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KAN-0439221 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KAN-0439782 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MPT-0B291 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Nexturastat A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ONCO-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QTX-125 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QTX-153 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • remetinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ricolinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit HDAC6 for Charcot-Marie-Tooth Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit HDAC6 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit HDAC6 for Oncology and Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit HDAC6 for Sepsis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit HDAC-6 for Autoimmune Disorders, Pancreatic Cancer and Charcot-Marie-Tooth Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit HDAC6 for Colorectal Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit HDAC6 for Neurodegenerative, Autoimmune and Inflammatory Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit HDAC6 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit HDAC6 for Oncology and Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Histone Deacetylase 6 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SP-259 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-3595 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit HDAC6 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vorinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Dormant Products
  • Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 18, 2017: Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial
      • May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting
      • Apr 07, 2017: Medivir announces positive data from the phase II study of remetinostat in patients with early-stage cutaneous T-cell lymphoma
      • Mar 08, 2017: Regenacy Pharmaceuticals Demonstrates Reversal of Chemotherapy-Induced Peripheral Neuropathy with HDAC6 Inhibitor Ricolinostat in Preclinical Model
      • Dec 04, 2016: Acetylon Presents Early Phase 1a/1b Results for Citarinostat (ACY-241) in Combination with Pomalyst and Dexamethasone Showing Promising Treatment Responses in Relapsed or Relapsed-and-Refractory Multiple Myeloma
      • Dec 02, 2016: Acetylon to present data on Ricolinostat at the American Society of Hematology Annual Meeting
      • Dec 02, 2016: Acetylon to present data on ACY-738 at the American Society of Hematology Annual Meeting
      • Dec 02, 2016: Acetylon to present data on Citarinostat at the American Society of Hematology Annual Meeting
      • Jun 13, 2016: Acetylon Presents Data on the Use of HDAC6 Inhibitor Ricolinostat (ACY-1215) in Combination with Pomalidomide and Dexamethasone for the Treatment of Multiple Myeloma
      • Jun 13, 2016: Acetylon Presents Data on the Use of HDAC6 Inhibitor ACY-241 in Combination with Pomalidomide and Dexamethasone for the Treatment of Multiple Myeloma
      • Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association
      • Jun 03, 2016: Acetylon Collaborators Publish ASCO Abstracts Demonstrating Immunomodulatory Properties of Ricolinostat in Preclinical Melanoma Models
      • Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting
      • Apr 20, 2016: Acetylon Announces the Presentation of Preclinical Data at AACR Supporting the Use of Selective HDAC6 Inhibition to Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology
      • Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Celgene Corp, H2 2017
  • Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
  • Pipeline by Curis Inc, H2 2017
  • Pipeline by HitGen LTD, H2 2017
  • Pipeline by Kancera AB, H2 2017
  • Pipeline by Karus Therapeutics Ltd, H2 2017
  • Pipeline by Medivir AB, H2 2017
  • Pipeline by Merck & Co Inc, H2 2017
  • Pipeline by Millennium Pharmaceuticals Inc, H2 2017
  • Pipeline by OnKure Inc, H2 2017
  • Pipeline by Quimatryx SL, H2 2017
  • Pipeline by Shuttle Pharmaceuticals LLC, H2 2017
  • Pipeline by Sigma-Tau SpA, H2 2017
  • Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Dormant Products, H2 2017 (Contd..2), H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top